Drug Libraray

DRACPC ID DRACPC0040

Active Ingredients Oglufanide

Description Glu-Trp is a dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage. It has a role as a metabolite, an immunomodulator, an angiogenesis modulating agent and an antineoplastic agent. It is functionally related to a L-glutamic acid and a L-tryptophan.

Synonyms Glu-trp; Glutamyltryptophan; L-Tryptophan, L-alpha-glutamyl-; Thymogen; Oglufanide

Type Small Molecule

Disease Colorectal Cancer, Ovarian Cancer, Kaposi's Sarcoma

Classification

Immunomodulator Peptide and derivative

Molecular Formula C16H19N3O5

Molecular Weight 333.34

Active Sequence EW

Sequence Length 2

Modification Not available

Structure

Show IUPAC/InChI/SMILES

IUPAC Name (4S)-4-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid

InChI InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1

InChI_Key LLEUXCDZPQOJMY-AAEUAGOBSA-N

SMILES O=C(O)CC[C@H](N)C(N[C@H](C(O)=O)CC1=CNC2=C1C=CC=C2)=O

PubChem CID 100094

DrugBank Accession Number DB05779

NCI Thesaurus Code C76274

UNII 4RHY598T5U GSRS

CAS 38101-59-6

Drug indication
Investigated for use/treatment in hepatitis (viral, C) and cancer.

The drug is not approved.

ClinicalTrials.gov Identifier	Title	Condition or disease	Phase	Purpose
NCT00003773	Phase I Study of Escalating Doses of IM-862 in Patients With Ovarian Cancer	Ovarian Cancer	Phase 1	Treatment
NCT00006037	Phase II Randomized Placebo-Controlled Double-Blinded Study With 5-FU vs. 5-FU With IM862 With Cross-Over to CPT-11 vs. CPT-11 With IM862	Colorectal Cancer	Phase 2	Treatment
NCT00017303	A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy	Ovarian Cancer; Primary Peritoneal Cavity Cancer	Phase 2	Treatment

More clinical information is obtained from ClinicalTrials.gov.